Bat virome

Biostrap CEO Goes Public With Biometric Changes After Contracting COVID-19 And Shares How His Wearable Alerted Him Prior To Diagnosis

Retrieved on: 
Tuesday, March 9, 2021
Respiratory diseases, Health, Bat virome, Sarbecovirus, Severe acute respiratory syndrome, Coronavirus disease, Medical specialties

"It was Biostrap's early warning notification that prompted me to schedule a nasal swab test, which confirmed the positive diagnosis of SARS-CoV-2," Sameer Sontakey, Biostrap CEO, said.

Key Points: 
  • "It was Biostrap's early warning notification that prompted me to schedule a nasal swab test, which confirmed the positive diagnosis of SARS-CoV-2," Sameer Sontakey, Biostrap CEO, said.
  • Although most patients with COVID-19 present with mild symptoms, they still show significant biometric changes, including resting heart rate, heart rate variability, oxygen saturation, respiratory rate and arterial properties.
  • In addition to the maladaptive changes in Sontakey's biometric trends, his sleep quality declined; sleep disruptions and duration increased significantly.
  • The Biostrap app is available for iOS on the Apple App Store and Android on the Google Play Store.

"Corona Virus Vaccine Market Size is Projected to reach 75.75 Billion by end of 2021, Says Brandessence Market Research"

Retrieved on: 
Tuesday, March 2, 2021
Coronaviridae, Medical specialties, Nidovirales, Zoonoses, Sarbecovirus, Bat virome, Vaccination, Virology, Human coronavirus 229E, Human coronavirus OC43, Coronavirus, Human coronavirus HKU1

The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.

Key Points: 
  • The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.
  • The study provides a crucial view of global corona virus vaccine market by segmenting the market based on infection type, vaccine type and region & country level.
  • Based on infection, the corona virus vaccine market is segmented into HCoV-229E, HCoV-OC43, HKU1-CoV, NL63, MERS-CoV, New Haven CoV, SARS-CoV and SARS-CoV-2.
  • Based on vaccine type, the market is segmented into S-protein based coronavirus vaccine, live attenuated coronavirus vaccine, inactivated coronavirus vaccine, MRNA vaccine and DNA-based vaccine.

"Corona Virus Vaccine Market Size is Projected to reach 75.75 Billion by end of 2021, Says Brandessence Market Research"

Retrieved on: 
Tuesday, March 2, 2021
Coronaviridae, Medical specialties, Nidovirales, Zoonoses, Sarbecovirus, Bat virome, Vaccination, Virology, Human coronavirus 229E, Human coronavirus OC43, Coronavirus, Human coronavirus HKU1

The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.

Key Points: 
  • The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.
  • The study provides a crucial view of global corona virus vaccine market by segmenting the market based on infection type, vaccine type and region & country level.
  • Based on infection, the corona virus vaccine market is segmented into HCoV-229E, HCoV-OC43, HKU1-CoV, NL63, MERS-CoV, New Haven CoV, SARS-CoV and SARS-CoV-2.
  • Based on vaccine type, the market is segmented into S-protein based coronavirus vaccine, live attenuated coronavirus vaccine, inactivated coronavirus vaccine, MRNA vaccine and DNA-based vaccine.

RGF® Environmental Group Releases Independent Test: PHI-PKG14 PHI-CELL® Inactivates greater than 99.9% of SARS-CoV-2 Virus in the Air and on Surfaces

Retrieved on: 
Friday, February 26, 2021
Sarbecovirus, Respiratory diseases, Zoonoses, Bat virome, Severe acute respiratory syndrome, Medical specialties, Disease transmission, Transmission of COVID-19, Draft:COVID-19 pandemic in Pakistan

"SARS-CoV-2 virus particles or aerosols are produced when an infected person coughs, sneezes or talks.

Key Points: 
  • "SARS-CoV-2 virus particles or aerosols are produced when an infected person coughs, sneezes or talks.
  • Large virus particles fall out of the air and onto surfaces, resulting in surface contamination, however small virus particles can stay airborne for hours," noted Dr. James Marsden, Executive Director of Science & Technology at RGF Environmental Group.
  • "Similar to RGF's REME HALO , the PHI-PKG14 PHI-CELL neutralizes greater than 99.9% of the SARS-CoV-2 virus in the air and on contaminated surfaces."
  • The PHI-PKG14 PHI-CELL eliminated the need for virus particles to travel through the HVAC system filters or UV air purification system.

Worldwide Immunoassay Industry Strategies and Trends to 2025 - Changing Technologies Spur Early Instrument Retirement - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 25, 2021
Biotechnology, Science, Health, Other Science, Sarbecovirus, Infectious diseases, Medical specialties, Zoonoses, Bat virome, Severe acute respiratory syndrome, Influenza

3.1.2 Changing Technologies Spur Early Instrument Retirement.

Key Points: 
  • 3.1.2 Changing Technologies Spur Early Instrument Retirement.
  • 3.3.2 Declining Cost of Instruments Changes Industry Structure.
  • Dx Companies Look at Multiplex Tests for SARS-CoV-2, Influenza
    6.2.4 Global Market by Application Segment Base vs.
  • Final
    6.3.4 Global Market by Technology Segment Base vs.

AIkido Pharma Provides Update on its Antiviral Platform, Including the Virus That Causes COVID-19

Retrieved on: 
Monday, February 22, 2021
Antiviral drugs, Medical specialties, Medicine, Health sciences, Zoonoses, Sarbecovirus, Bat virome, Broad-spectrum antiviral drug, Viruses, Coronavirus, Severe acute respiratory syndrome coronavirus, Coronavir

These new compounds are currently being tested against Influenza virus with testing on SARS-CoV-2 in the near future.

Key Points: 
  • These new compounds are currently being tested against Influenza virus with testing on SARS-CoV-2 in the near future.
  • Subsequently, the top analogs from eachseries of leadcompounds will be selected for tests of their anti-viral effects in a SARS-CoV-2 mouse model.
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.
  • The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope™ Monoclonal Antibody Cocktail Candidate Against COVID-19

Retrieved on: 
Friday, February 19, 2021
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Sarbecovirus, Zoonoses, Animal diseases, Medicine, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Coronavirus disease, Variants of SARS-CoV-2, IPA’s PolyTope Platform., ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) (TSX Venture: IPA) announced preliminary, preclinical data in hamsters of IPAs proprietary TATX-03 PolyTope antibody cocktail program against SARS-CoV-2, the virus that causes COVID-19 disease.

Key Points: 
  • ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) (TSX Venture: IPA) announced preliminary, preclinical data in hamsters of IPAs proprietary TATX-03 PolyTope antibody cocktail program against SARS-CoV-2, the virus that causes COVID-19 disease.
  • The results of the preclinical study demonstrated the potential of IPAs TATX-03 antibody cocktail to provide strong anti-viral effects against SARS-CoV-2 in both prophylactic (preventative) and treatment settings.
  • IPAs TATX-03 PolyTope antibody cocktail was administered as a single dose to hamsters that had been infected with the SARS-CoV-2 variant.
  • The study showed that IPAs antibody cocktail cleared the lungs of detectable replication-competent virus in 100% of the SARS-CoV-2 infected hamsters by day 4 post-infection.

SARS-CoV-2 in mink: recommendations to improve monitoring

Retrieved on: 
Thursday, February 18, 2021
Coronaviridae, Sarbecovirus, Health, Fur trade, Bat virome, Mink, Mustelinae, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Coronavirus, Fur farming, European Centre for Disease Prevention and Control

Early detection of SARS-CoV-2 (coronavirus) should be a priority objective for monitoring activities at mink farms in the European Union, a new report recommends.

Key Points: 
  • Early detection of SARS-CoV-2 (coronavirus) should be a priority objective for monitoring activities at mink farms in the European Union, a new report recommends.
  • The report, compiled by EFSA and the European Centre for Disease Prevention and Control (ECDC), proposes options for monitoring strategies that will help to prevent and control spread of the disease.
  • It concludes that all mink farms should be considered at risk from SARS-CoV-2 and that monitoring should include active measures such as testing of animals and staff in addition to passive surveillance by farmers and veterinarians.
  • The report was requested by the European Commission following outbreaks of SARS-CoV-2 in mink farms across Europe in 2020.

BD Announces Emergency Use Authorization, CE Mark for Combination Molecular Diagnostic to Detect SARS-CoV-2, Influenza A+B in Single Test

Retrieved on: 
Friday, February 12, 2021
Sarbecovirus, Zoonoses, Animal diseases, Respiratory diseases, Bat virome, Severe acute respiratory syndrome, BD, COVID-19 testing, DiaSorin

This ability to detect these new variants also applies to the standalone SARS-CoV-2 test for the BD MAX System.

Key Points: 
  • This ability to detect these new variants also applies to the standalone SARS-CoV-2 test for the BD MAX System.
  • The BD SARS-CoV-2/Flu assay is run on the BD MAX System and distinguishes between SARS-CoV-2 and Influenza A+B, providing a positive or negative result for each virus using a single specimen.
  • The BD SARS-CoV-2/Flu for BD MAX System kits are now available for order in the United States and Europe.
  • The BD MAX System is a molecular diagnostic platform already in use at thousands of laboratories worldwide.

GATC Health Introduces Personalized Immunity Platform to Predict Individual Response to SARS-CoV-2 and Other Viral Infections

Retrieved on: 
Thursday, February 11, 2021
Biotechnology, Technology, Other Consumer, Health, Pharmaceutical, Research, Infectious diseases, Software, Genetics, Consumer, Science, Medical specialties, Epidemiology, Immunology, Medicine, Health sciences, Bat virome, Sarbecovirus, Severe acute respiratory syndrome, Infection, Immunity

VIP can predict the likelihood of infection and severity of outcomes for SARS-CoV-2 and other viral infections.

Key Points: 
  • VIP can predict the likelihood of infection and severity of outcomes for SARS-CoV-2 and other viral infections.
  • MAT integrates personal metadata to accurately predict individual immunity response to agents compromising the immune system.
  • GATC Healths Viral Immunity Platform will provide customers with a personalized report outlining predicted viral infection risk, immunity response, and potential complications.
  • GATC Health is a pioneering technology company using Predictive Multiomics to advance drug discovery and improve human health.